Results 91 to 100 of about 91,337 (260)
This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley +1 more source
Improvement of neuropsychological performances and reduction of immune-activation markers after probiotic supplementation and change of life-style in an HIV positive male: targeting the microbiota to act on gut-brain axis [PDF]
The gut-brain axis is widely in uenced by the intestinal microbiota and dysbiosis is consequently associated with a large dysregulation of its functions. Probiotic supplementation, reducing the harmful effects of dysbiosis, has shown positive effects not
Bianchi, Luigi +8 more
core
Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. [PDF]
Mucosa-associated invariant T (MAIT) cell loss in chronic HIV-1 infection is a significant insult to antimicrobial immune defenses. Here we investigate the response of MAIT cells during acute HIV-1 infection utilizing the RV217 cohort with paired ...
Ananworanich, Jintanat +23 more
core
Human umbilical cord blood-borne fibroblasts contain marrow niche precursors that form a bone/marrow organoid in vivo [PDF]
Human umbilical cord blood (CB) has attracted much attention as a reservoir for functional hematopoietic stem and progenitor cells, and, recently, as a source of blood-borne fibroblasts (CB-BFs). Previously, we demonstrated that bone marrow stromal cell (
Biondi, Andrea +11 more
core +2 more sources
Objective Systemic lupus erythematosus (SLE) is characterized by increased Type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama +16 more
wiley +1 more source
Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab
Marilyn T Nedumcheril,1,2 Robert A DeSimone,1 Sabrina E Racine-Brzostek,1 Ok Kyong Chaekal,1,3 Ljiljana V Vasovic1 1Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA; 2New York ...
Nedumcheril MT +4 more
doaj
Objective The spontaneous K/BxN mouse model of rheumatoid arthritis has been used extensively to study chronic inflammation, contribution of immune cells, and the primordial role of autoreactive antibodies in disease initiation and severity. Only the ubiquitous enzyme glucose‐6‐phosphate isomerase (GPI) is the target of IgG autoantibodies secreted by ...
Thibault Vanhoucke +8 more
wiley +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
. In case of hepatitis C the adequate adaptive immune response depends on T-helper lymphocyte subsets and recruiting specific T cells in the site of infection.
D. S. Elezov +6 more
doaj +1 more source
Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody-Positive Myasthenia Gravis. [PDF]
Current plasma cell–targeting therapies lack antigen specificity. Using an antibody‐mediated cytotoxicity engager (ACE) targeting the α‐subunit of the extracellular domain of the human acetylcholine receptor (hAChR αECD), we selectively depleted pathogenic antibody‐secreting cells in a myasthenia gravis model, reducing autoantibody titers and disease ...
Khodadadi L +16 more
europepmc +2 more sources

